Perl Alexander E, Martinelli Giovanni, Cortes Jorge E, Neubauer Andreas, Berman Ellin, Paolini Stefania, Montesinos Pau, Baer Maria R, Larson Richard A, Ustun Celalettin, Fabbiano Francesco, Erba Harry P, Di Stasi Antonio, Stuart Robert, Olin Rebecca, Kasner Margaret, Ciceri Fabio, Chou Wen-Chien, Podoltsev Nikolai, Recher Christian, Yokoyama Hisayuki, Hosono Naoko, Yoon Sung-Soo, Lee Je-Hwan, Pardee Timothy, Fathi Amir T, Liu Chaofeng, Hasabou Nahla, Liu Xuan, Bahceci Erkut, Levis Mark J Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML. , The New England journal of medicine, 381(18): 2019,1728-1740
McMahon Christine M, Ferng Timothy, Canaani Jonathan, Wang Eunice S, Morrissette Jennifer J D, Eastburn Dennis J, Pellegrino Maurizio, Durruthy-Durruthy Robert, Watt Christopher D, Asthana Saurabh, Lasater Elisabeth A, DeFilippis RosaAnna, Peretz Cheryl A C, McGary Lisa H F, Deihimi Safoora, Logan Aaron C, Luger Selina M, Shah Neil P, Carroll Martin, Smith Catherine C, Perl Alexander E Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. , Cancer discovery, 9(8): 2019,1050-1063
Brown FC, Wang X, Birkinshaw RW, Chua CC, Morley TD, Kasapgil S, Pomilio G, Blombery P, Huang DCS Professor, Czabotar PE, Priore SF, Yang G, Carroll MP, Wei AH, Perl AE. Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia , Blood Adv. , 9: 2024,127-131
Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly L, Kim HJ, Mikesch JH, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Geller NL, Hasabou N, Delgado D, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Wittsack H, Mendizabal A, Devine SM, Horowitz MM, Chen YB; BMT-CTN 1506/MORPHO Study Investigators. Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3 , J Clin Oncol, 42: 2024,1766-1775
Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, Žák P, Wang PN, Mitov T, Hanyok J, Kamel YM, Rohrbach JEC, Liu L, Benzohra A, Lesegretain A, Cortes J, Perl AE, Sekeres MA, Dombret H, Amadori S, Wang J, Levis MJ, Schlenk RF; QuANTUM-First Study Group. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial , Lancet, 401: 2023,1571-1583
Smith Catherine C, Zhang Chao, Lin Kimberly C, Lasater Elisabeth A, Zhang Ying, Massi Evan, Damon Lauren E, Pendleton Matthew, Bashir Ali, Sebra Robert, Perl Alexander, Kasarskis Andrew, Shellooe Rafe, Tsang Garson, Carias Heidi, Powell Ben, Burton Elizabeth A, Matusow Bernice, Zhang Jiazhong, Spevak Wayne, Ibrahim Prabha N, Le Mai H, Hsu Henry H, Habets Gaston, West Brian L, Bollag Gideon, Shah Neil P Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397. , Cancer Discovery, 5(6): 2015,668-79
Perl AE*, Altman JK*, Cortes JE, Smith CC, Litzow M, Baer MR, Claxton D. Erba H, Gill S, Goldberg S, Jurcic JA, Larson RA, Liu C, Ritchie EK, Sargent B, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart RK, Röllig C, Neubauer A, Martinelli G, Bahceci E, Levis MJ (*equal contribution) Selective Inhibition of FLT3 by Gilteritinib in Relapsed/Refractory Acute Myeloid Leukaemia: a
Multicentre, First-in-human, Open-label, Phase 1/2 Study , Lancet Oncology: 2017
Nybakken G E, Canaani J, Roy D, Morrissette J D, Watt C D, Shah N P, Smith C C, Bagg A, Carroll M, Perl A E Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone. , Leukemia, 30(6): 2015,1422-5
Li Sheng, Garrett-Bakelman Francine, Perl Alexander E, Luger Selina M, Zhang Chao, To Bik L, Lewis Ian D, Brown Anna L, D Andrea Richard J, Ross M, Levine Ross, Carroll Martin, Melnick Ari, Mason Christopher E Dynamic evolution of clonal epialleles revealed by methclone. , Genome Biology, 15(9): 2014,472
Smith Catherine Choy, Lasater Elisabeth A, Lin Kimberly C, Wang Qi, McCreery Melissa Quino, Stewart Whitney K, Damon Lauren E, Perl Alexander E, Jeschke Grace R, Sugita Mayumi, Carroll Martin, Kogan Scott C, Kuriyan John, Shah Neil P Crenolanib is a selective type I pan-FLT3 inhibitor. , Proceedings of the National Academy of Sciences of the United States of America, 111(14): 2014,5319-24
